# The role and mechanism of FTO in leukemogenesis and drug response

> **NIH NIH R01** · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · 2020 · $426,319

## Abstract

PROJECT SUMMARY (ABSTRACT):
 Background: The identification of FTO as the first N6-methyladenosine RNA demethylase have spurred
immense interest in study of the regulatory functions of m6A modifications. Despite the critical impacts of the
m6A modifications in various fundamental biological processes, the function (and molecular mechanism) of
FTO in cancers, such as acute myeloid leukemia (AML), has yet to be studied. AML is one of the most
common and fatal forms of hematopoietic malignancies. Despite the improved risk stratifications and treatment-
adapted strategies, >70% of AML patients cannot survive over 5 years due to drug resistance. Thus, it is critical
to better understand molecular mechanisms underlying pathogenesis and drug response of AML, which may lead to
the development of effective novel therapeutic strategies to treat AML. Our data suggest that FTO likely plays a
critical oncogenic role in the pathogenesis of MLL-rearranged AML and in drug response of t(15;17) AML. We
show that FTO is highly expressed in AMLs carrying t(11q23)/MLL-rearrangements, t(15;17), NPM1 mutations
and/or FLT3-ITD, namely FTO-high AMLs, which are more sensitive to all-trans-retinoic acid (ATRA) and/or
arsenic trioxide (ATO) treatment than the other AML subtypes. ATRA/ATO-based differentiation therapy has
transformed t(15;17) AML from a highly fatal disease to a highly curable one. However, the role of FTO and the
underlying molecular mechanism in the pathogenesis and drug response of FTO-high AMLs are elusive.
 Objective/Hypothesis: We hypothesize that FTO, as a major m6A eraser, plays a critical role in both
pathogenesis and drug response of FTO-high AMLs through epigenetically regulating expression of its targets.
 Specific Aims: (1) To determine the role of FTO in both development and maintenance of FTO-high
AMLs; (2) To identify critical direct targets of FTO and the regulatory mechanism(s) in FTO-high AMLs; and (3)
To determine the role and underlying mechanism of FTO in the response of FTO-high AMLs to ATRA and/or
ATO treatment.
 Study Design: 1) We will use the Fto knockout model coupled with mouse bone marrow transplantation
(BMT) leukemia models to investigate the pathological function of FTO in both development and maintenance
of various subtypes of FTO-high AMLs and in the self-renewal of relevant leukemia stem/initiating cells
(LSCs/LICs). 2) We will identify critical direct target genes of FTO by integrating m6A distribution data with
FTO-RNA interaction data, and will decipher the molecular mechanism(s) by which FTO post-transcriptionally
regulates expression of its direct target genes, followed by functional studies of the top candidate targets of
FTO in the pathogenesis of FTO-high AMLs. 3) We will use both mouse BMT leukemia models and patient-
derived xeno-transplantation models to determine the role and underlying molecular mechanism of FTO in the
response of FTO-high AMLs to ATRA and/or ATO treatment. The critical target genes of FTO and...

## Key facts

- **NIH application ID:** 9879719
- **Project number:** 5R01CA214965-05
- **Recipient organization:** BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
- **Principal Investigator:** Jianjun Chen
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $426,319
- **Award type:** 5
- **Project period:** 2017-04-01 → 2022-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9879719

## Citation

> US National Institutes of Health, RePORTER application 9879719, The role and mechanism of FTO in leukemogenesis and drug response (5R01CA214965-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9879719. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*